|
[Related PubMed/MEDLINE]
Total Number of Papers: 150
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2023 |
AMPK-like proteins and their function in female reproduction and gynecologic cancer. |
AMPK, LKB1 |
| 2 |
2023 |
ANKRD22 promotes glioma proliferation, migration, invasion, and epithelial-mesenchymal transition by upregulating E2F1-mediated MELK expression. |
ANKRD22, E2F1 |
| 3 |
2023 |
Differential Effects of Overexpression of Wild Type and Kinase-Dead MELK in Fibroblasts and Keratinocytes, Potential Implications for Skin Wound Healing and Cancer. |
--- |
| 4 |
2023 |
Maternal embryonic leucine zipper kinase in tumor cells and tumor microenvironment: An emerging player and promising therapeutic opportunity. |
AMPK |
| 5 |
2023 |
Network Pharmacology and Experimental Validation to Explore the Effect and Mechanism of Kanglaite Injection Against Triple-Negative Breast Cancer. |
AURKA, CDC25A, Cdc25B, CDK1, CDK2, CHEK1, GO, KEGG, KLTi, PPI, TNBC |
| 6 |
2023 |
Structure-based virtual screening of chemical libraries as potential MELK inhibitors and their therapeutic evaluation against breast cancer. |
TNBC |
| 7 |
2022 |
Comprehensive analysis to identify noncoding RNAs mediated upregulation of maternal embryonic leucine zipper kinase (MELK) correlated with poor prognosis in hepatocellular carcinoma. |
C-index, HCC, ICGC, ncRNAs, OS, TCGA-LIHC |
| 8 |
2022 |
Computational exploration of maternal embryonic leucine zipper kinase (MELK) as a cancer drug target. |
RMSD |
| 9 |
2022 |
Identification of biomarkers related to tumorigenesis and prognosis in breast cancer. |
CCNA2, CDK1, CENPF, DEGs, GEPIA, HPA, KIF2C, KIF4A, PBK, PPI, PRC1, TPX2, UALCAN |
| 10 |
2022 |
LncRNA OSTM1-AS1 acts as an oncogenic factor in Wilms' tumor by regulating the miR-514a-3p/MELK axis. |
lncRNAs, OSTM1-AS1, WT |
| 11 |
2022 |
Maternal embryonic leucine zipper kinase (MELK) optimally regulates the HIV-1 uncoating process. |
HIV-1 |
| 12 |
2022 |
Maternal embryonic leucine zipper kinase serves as a potential prognostic marker and leads to sorafenib chemoresistance modified by miR-142-5p in hepatocellular carcinoma. |
DAVID, HCC, HCC/SR, RT-PCR |
| 13 |
2022 |
MELK is a prognostic biomarker and correlated with immune infiltration in glioma. |
CGGA, DEGs, GEO, GSEA, ssGSEA |
| 14 |
2022 |
MELK predicts poor prognosis and promotes metastasis in esophageal squamous cell carcinoma via activating the NF‑kappaB pathway. |
ESCC, IKK |
| 15 |
2022 |
Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer. |
ACC, CDK |
| 16 |
2022 |
Structural classification of MELK inhibitors and prospects for the treatment of tumor resistance: A review. |
--- |
| 17 |
2022 |
Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer. |
BLBC, CN, DCIS, IDC, IHC, TNBC |
| 18 |
2021 |
A novel carbon-11 radiolabeled maternal embryonic leucine zipper kinase inhibitor for PET imaging of triple-negative breast cancer. |
HPLC, PET, TNBC |
| 19 |
2021 |
A synthetic lethal screen identifies HDAC4 as a potential target in MELK overexpressing cancers. |
SCF |
| 20 |
2021 |
AMPKalpha-like proteins as LKB1 downstream targets in cell physiology and cancer. |
AMP, AMPKalpha, BRSKs, LKB1, MARKs, SIK, UV |
| 21 |
2021 |
Analysis of crucial genes, pathways and construction of the molecular regulatory networks in vascular smooth muscle cell calcification. |
COs, CVSMCs, DANCR, DEGs, DETF, ECM, FOX, lncRNA, SNAI2, TFs, VC, VSMCs |
| 22 |
2021 |
Circ_0007031 Silencing Inhibits Cell Proliferation and Induces Cell Apoptosis via Downregulating MELK at a miR-485-3p-Dependent Way in Colorectal Cancer. |
circRNA, CRC, EdU, miR-485-3p, qRT-PCR |
| 23 |
2021 |
Consensus Virtual Screening Identified [1,2,4]Triazolo[1,5-b]isoquinolines As MELK Inhibitor Chemotypes. |
--- |
| 24 |
2021 |
Ectopic expression of MELK in oral squamous cell carcinoma and its correlation with epithelial mesenchymal transition. |
EMT, OSCC |
| 25 |
2021 |
Functional genomics for breast cancer drug target discovery. |
--- |
| 26 |
2021 |
KLF5-induced BBOX1-AS1 contributes to cell malignant phenotypes in non-small cell lung cancer via sponging miR-27a-5p to up-regulate MELK and activate FAK signaling pathway. |
BBOX1-AS1, lncRNA, NSCLC |
| 27 |
2021 |
Maternal embryonal leucine zipper kinase immunoreactivity in atypical teratoid/rhabdoid tumors: a study of 50 cases. |
IHC |
| 28 |
2021 |
MELK expression in breast cancer is associated with infiltration of immune cell and pathological compete response (pCR) after neoadjuvant chemotherapy. |
AJCC, CYT, IFN, pCR, TNBC |
| 29 |
2021 |
MELK Inhibition Effectively Suppresses Growth of Glioblastoma and Cancer Stem-Like Cells by Blocking AKT and FOXM1 Pathways. |
AKT, FOXM1, GBM, GSCs |
| 30 |
2021 |
Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line. |
--- |
| 31 |
2021 |
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. |
AML, eIF4B, FLT3, TKIs |
| 32 |
2021 |
Up-regulation of MELK by E2F1 promotes the proliferation in cervical cancer cells. |
--- |
| 33 |
2021 |
[18F]F-ET-OTSSP167 Targets Maternal Embryo Leucine Zipper Kinase for PET Imaging of Triple-Negative Breast Cancer. |
TNBC |
| 34 |
2020 |
Ablation of AMPK-Related Kinase MPK38/MELK Leads to Male-Specific Obesity in Aged Mature Adult Mice. |
LH, MPK38 |
| 35 |
2020 |
An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases. |
JAK3 |
| 36 |
2020 |
Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2]. |
AEs, CC, DR, FOXM1, HIG-2, HJURP, OC, PS, URLC10, VEGFR |
| 37 |
2020 |
Anticancer Agents Based on Vulnerable Components in a Signalling Pathway. |
Chk1, IAP, MDM2, ROS1, SK2, WEE1 |
| 38 |
2020 |
Cloning, tissue distribution, expression pattern, and function of porcine maternal embryonic leucine zipper kinase. |
pMELK, STS, SUVEC |
| 39 |
2020 |
Enigmatic MELK: The controversy surrounding its complex role in cancer. |
TNBC |
| 40 |
2020 |
High expression of maternal embryonic leucine-zipper kinase (MELK) impacts clinical outcomes in patients with ovarian cancer and its inhibition suppresses ovarian cancer cells growth ex vivo. |
mRNA |
| 41 |
2020 |
Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells. |
CDK1, MIB/MS |
| 42 |
2020 |
Maternal Embryonic Leucine Zipper Kinase Promotes Tumor Growth and Metastasis via Stimulating FOXM1 Signaling in Esophageal Squamous Cell Carcinoma. |
ESCC |
| 43 |
2020 |
Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in osteosarcoma. |
--- |
| 44 |
2020 |
Maternal embryonic leucine zipper kinase: A novel biomarker and a potential therapeutic target in lung adenocarcinoma. |
GEPIA, LUAD |
| 45 |
2020 |
MELK Accelerates the Progression of Colorectal Cancer via Activating the FAK/Src Pathway. |
--- |
| 46 |
2020 |
MELK promotes Endometrial carcinoma progression via activating mTOR signaling pathway. |
EC |
| 47 |
2020 |
MELK/MPK38 in cancer: from mechanistic aspects to therapeutic strategies. |
MPK38 |
| 48 |
2020 |
microRNA-375 released from extracellular vesicles of bone marrow mesenchymal stem cells exerts anti-oncogenic effects against cervical cancer. |
BMSCs, EVs, miRNAs, TEM |
| 49 |
2020 |
Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1. |
TNBC |
| 50 |
2020 |
Phillygenin, a MELK Inhibitor, Inhibits Cell Survival and Epithelial-Mesenchymal Transition in Pancreatic Cancer Cells. |
DFS, EMT, OS, PC, PHI |
| 51 |
2020 |
Resistance to drugs and cell death in cancer stem cells (CSCs). |
CSCs, IAPs, mTOR, PI3K |
| 52 |
2019 |
5-Keto-3-cyano-2,4-diaminothiophenes as selective maternal embryonic leucine zipper kinase inhibitors. |
--- |
| 53 |
2019 |
Arrestin-3 interaction with maternal embryonic leucine-zipper kinase. |
--- |
| 54 |
2019 |
Crystal structure of Maternal Embryonic Leucine Zipper Kinase (MELK) in complex with dorsomorphin (Compound C). |
--- |
| 55 |
2019 |
Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrrolo[2,3-b]pyridine derivatives as potential anti-tumor agents. |
--- |
| 56 |
2019 |
EZH2 Phosphorylation Promotes Self-Renewal of Glioma Stem-Like Cells Through NF-kappaB Methylation. |
CSCs, EZH2, GSCs |
| 57 |
2019 |
Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma. |
EZH2, FOXM1, iCCA, IHC, siRNA |
| 58 |
2019 |
Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma. |
EZH2, PRC2 |
| 59 |
2019 |
Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma. |
DLBCL, MCL |
| 60 |
2019 |
MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors. |
AT/RT, BBB, CNS, MEK, SHH |
| 61 |
2019 |
MELK inhibition targets cancer stem cells through downregulation of SOX2 expression in head and neck cancer cells. |
CSCs, HNSCC, SOX2, TFs |
| 62 |
2019 |
MELK is Upregulated in Advanced Clear Cell Renal Cell Carcinoma and Promotes Disease Progression by Phosphorylating PRAS40. |
ccRCC, DEGs, mTORC1 |
| 63 |
2019 |
Thr55 phosphorylation of p21 by MPK38/MELK ameliorates defects in glucose, lipid, and energy metabolism in diet-induced obese mice. |
AMPK, CDK, MDM2, MPK38, PPARgamma |
| 64 |
2018 |
A Conditional Dependency on MELK for the Proliferation of Triple-Negative Breast Cancer Cells. |
--- |
| 65 |
2018 |
Caenorhabditis elegans ced-3 Caspase Is Required for Asymmetric Divisions That Generate Cells Programmed To Die. |
--- |
| 66 |
2018 |
Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma. |
ACC |
| 67 |
2018 |
Identify Cross Talk Between Circadian Rhythm and Coronary Heart Disease by Multiple Correlation Analysis. |
CELF, CFL1, GNAO1, GNB1, MAP4, MYH7, PRKCG, QKI, TUBA1C |
| 68 |
2018 |
Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia. |
CLL |
| 69 |
2018 |
Maternal embryonic leucine zipper kinase: A novel biomarker and a potential therapeutic target of cervical cancer. |
--- |
| 70 |
2018 |
MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells. |
JNK, TNBC |
| 71 |
2018 |
MELK expression correlates with tumor mitotic activity but is not required for cancer growth. |
--- |
| 72 |
2018 |
MELK Inhibition in Diffuse Intrinsic Pontine Glioma. |
BBB, DIPG |
| 73 |
2018 |
MELK is a novel therapeutic target in high-risk neuroblastoma. |
NB, pRb |
| 74 |
2018 |
Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer. |
FOXM1 |
| 75 |
2018 |
Sanguinarine triggers intrinsic apoptosis to suppress colorectal cancer growth through disassociation between STRAP and MELK. |
CRC, ROS, STRAP |
| 76 |
2018 |
Structure-based discovery of new maternal embryonic leucine zipper kinase inhibitors. |
FAK |
| 77 |
2017 |
Caenorhabditis elegans CES-1 Snail Represses pig-1 MELK Expression To Control Asymmetric Cell Division. |
NSM |
| 78 |
2017 |
CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials. |
--- |
| 79 |
2017 |
Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth. |
TNBC |
| 80 |
2017 |
Dual Functions of Cyclometalated Iridium(III) Complexes: Anti-Metastasis and Lysosome-Damaged Photodynamic Therapy. |
--- |
| 81 |
2017 |
Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant. |
TNBC |
| 82 |
2017 |
Maternal embryonic leucine zipper kinase (MELK) reduces replication stress in glioblastoma cells. |
--- |
| 83 |
2017 |
Maternal embryonic leucine zipper kinase inhibits epithelial-mesenchymal transition by regulating transforming growth factor-beta signaling. |
EMTs, TGF-beta |
| 84 |
2017 |
Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma. |
--- |
| 85 |
2017 |
MELK and EZH2 Cooperate to Regulate Medulloblastoma Cancer Stem-like Cell Proliferation and Differentiation. |
EZH2 |
| 86 |
2017 |
MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells. |
EOC |
| 87 |
2017 |
MELK is not necessary for the proliferation of basal-like breast cancer cells. |
BBC |
| 88 |
2017 |
MELK Promotes Melanoma Growth by Stimulating the NF-kappaB Pathway. |
SILAC |
| 89 |
2017 |
MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies. |
TNBC |
| 90 |
2017 |
MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis. |
HCC, miR-214-3p, OS, qRT-PCR, RFS |
| 91 |
2017 |
Phosphorylation of the HIV-1 capsid by MELK triggers uncoating to promote viral cDNA synthesis. |
--- |
| 92 |
2017 |
The microRNA expression signature of small cell lung cancer: tumor suppressors of miR-27a-5p and miR-34b-3p and their targeted oncogenes. |
CENPF, miRNA, SCLC, SOX1, TOP2A |
| 93 |
2017 |
The target landscape of clinical kinase drugs. |
SIK2 |
| 94 |
2017 |
Up-Regulated Maternal Embryonic Leucine Zipper Kinase Predicts Poor Prognosis of Hepatocellular Carcinoma Patients in a Chinese Han Population. |
HCC |
| 95 |
2016 |
Development of small molecular compounds targeting cancer stem cells. |
CSCs, TTK |
| 96 |
2016 |
Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. |
CSCs, SCLC |
| 97 |
2016 |
Expression of Maternal Embryonic Leucine Zipper Kinase (MELK) Correlates to Malignant Potentials in Hepatocellular Carcinoma. |
HCC, OS, PCR, PIVKA-II, RFS |
| 98 |
2016 |
Identification of IL11RA and MELK amplification in gastric cancer by comprehensive genomic profiling of gastric cancer cell lines. |
IL11RA |
| 99 |
2016 |
Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer. |
TNBC |
| 100 |
2016 |
MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence. |
HCC |
|
A Search Service for Abbreviation / Long Form
